Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.